Files and links (1)
CC BY V4.0, Open Access
Journal article
The incidence of anti-HMGCR immune-mediated necrotising myopathy: an Australian and UK retrospective multi-site cohort study
Rheumatology (Oxford, England), Vol.64(9), pp.4995-5003
2025
PMID: 40347460
Abstract
Immune-mediated necrotising myopathy (IMNM) with autoantibodies targeting 3-hydroxy-3-methylglutaryl-CoA reductase (anti-HMGCR) is considered a rare complication of statin therapy. We calculate the incidence of anti-HMGCR IMNM and describe clinical characteristics in four independent cohorts: Manchester (UK), Bristol (UK), Western Australia (WA, Australia) and South Australia (SA, Australia).
Adults (≥18 years) with anti-HMGCR IMNM (ENMC criteria; 2018-2023) were identified from myositis clinic and laboratory records. Nationwide UK anti-HMGCR testing was performed at Oxford University Hospital Laboratories and state-based WA/SA testing at PathWest Laboratories.
109 anti-HMGCR IMNM cases were identified (51% female, median 66 years [IQR 58-72.2]) with median follow-up 2.3 years [IQR 1.5-4.2]. Mean annual incidence was 2.9 cases/million person-years. In statin-users, incidence was 20.4 (UK) and 24.1 (WA/SA) cases/million statin-users/year. 101 patients were statin-exposed, mostly atorvastatin (77/101, 76.2%). Median statin duration before diagnosis was 3 years (range: 1 month-23 years). Eight (7.5%) were statin-naïve and compared with statin-exposed patients, younger (median 46.1 vs 67 years, p= 0.02), frequently of non-white ethnicity (5/8 vs 20/77, p= 0.04) and more commonly had dysphagia (4/8 vs 14/94, p= 0.03). The median peak creatine kinase (CK) was 7,020 IU/l (range: 964-39 076). 48/105 (45.7%) received intravenous immunoglobulin. At follow-up, less than half had normal CK (50/105 [47.6%]) or muscle power (48/104 [46.2%]).
For the first time, we have calculated an incidence of anti-HMGCR IMNM using a large, multinational cohort. We highlight the refractory nature of anti-HMGCR IMNM. We also describe the unique phenotype of statin-naïve anti-HMGCR IMNM, and the rare occurrence of self-limiting myopathy.
Details
- Title
- The incidence of anti-HMGCR immune-mediated necrotising myopathy: an Australian and UK retrospective multi-site cohort study
- Authors/Creators
- Thomas Khoo - Royal Adelaide HospitalElina Tan - Sir Charles Gairdner HospitalVidya Limaye - Royal Adelaide HospitalHarsha Gunawardena - North Bristol NHS TrustRoss Sadler - Churchill HospitalJanine A Lamb - University of ManchesterXia Lyu - University of ManchesterAnna Brusch - Pathwest Laboratory MedicineMerrilee Needham - Fiona Stanley HospitalKeziah Austin - North Bristol NHS TrustAaron Bahadori - Fiona Stanley HospitalMaya H Buch - University of ManchesterMaciej Tomaszewski - University of ManchesterJames B Lilleker - Manchester Academic Health Science CentreHector Chinoy - University of Manchester
- Publication Details
- Rheumatology (Oxford, England), Vol.64(9), pp.4995-5003
- Publisher
- Oxford University Press on behalf of the British Society for Rheumatology.
- Number of pages
- 9
- Identifiers
- 991005780607907891
- Copyright
- © The Author(s) 2025.
- Murdoch Affiliation
- Health Futures Institute; Personalised Medicine Centre
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
4 File views/ downloads
14 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.106 Rheumatology
- 1.106.1684 Dermatomyositis
- Web Of Science research areas
- Rheumatology
- ESI research areas
- Clinical Medicine